Current pharmacological treatment of hepatocellular carcinoma. (October 2021)

• Record Type: Journal Article
• Authors: Muñoz-Martínez, Sergio; Iserte, Gemma; Sanduzzi-Zamparelli, Marco; Llarch, Neus; Reig, Maria
• Is Part Of: Current opinion in pharmacology. Volume 60(2021)
• Page Start: 141
• Page End: 148
• Publication Date: 2021-10
• Subjects: Pharmacology -- Periodicals; Pharmaceutical Preparations -- Periodicals; Drug Therapy -- Periodicals; Biopharmaceutics -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Periodicals; 615.105
• DOI: 10.1016/j.coph.2021.07.009
• Languages: English
• ISSNs: 1471-4892

Abstract

Abstract: The landscape of hepatocellular carcinoma (HCC) has changed since the incorporation of sorafenib in 2007 as the first pharmacological treatment for HCC. The combination of atezolizumab plus bevacizumab is currently the first-line treatment for HCC patients, and there are several second-line options approved for patients who had received sorafenib as the first-line treatment. The advantage of having multiple options of pharmacological treatment for HCC patients is associated to the need to redefine the clinical decision-making approach and considering new endpoints for the clinical trials design. The aim of this review was to share the Barcelona Clinic Liver Cancer approach and to summarize the ongoing clinical trials, which are testing pharmacological treatments.